SK Bioscience

SK bioscience is a leading South Korean vaccine and biotech company with innovative R&D and cutting-edge manufacturing systems. SK bioscience developed the world's first quadrivalent cell-cultured influenza vaccine, SKYCellflu with obtaining WHO PQ (Pre-qualification) certification in 2019 followed by developing SKYZoster, the world's second shingles vaccine, and SkyVaricella, the world's second WHO PQ-certified chickenpox vaccine. SK bioscience is expanding its R&D pipeline through global partnerships with public and private institutions, and is planning to commercialize a pneumococcal conjugate vaccine, cervical cancer vaccine, typhoid conjugate vaccine, and rotavirus vaccine. In the recent COVID-19 pandemic, SK bioscience has established a fast pandemic response system and has grown into a global vaccine company attracting attention in the world. SK bioscience signed a CMO contract to manufacture AstraZeneca's COVID-19 vaccine from drug substance to drug product at L-House, SK’s vaccine manufacturing plant, and contributed to the early prevention of COVID-19, recognized as a global hub for vaccine manufacturing. In addition, through international cooperation with the Bill & Melinda Gates Foundation, CEPI, GSK, etc., SK bioscience is developing a Korea's first recombinant protein-based COVID-19 vaccine, 'SKYCovione', and a universal vaccine to prevent ‘Sarbecovirus.’ Based on its technology, all SK bioscience colleagues are trying to achieve the company’s mission, ‘We promote human health, from prevention to cure.’ To meet social expectations, SK bioscience will build trust as a global innovative partner of vaccine and biotech so that all stakeholders, including employees, customers, shareholders, and local communities, could be proud and happy.